Logotipo del repositorio
Logotipo del repositorio
 

Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_16eceng
dc.contributor.advisorTrindade, Cristiano
dc.contributor.authorNavarro Gamarra, Marco André
dc.contributor.authorMogollon Oñoro, Cesar Alexandro
dc.contributor.authorPastrana Donado, Steven Alberto
dc.date.accessioned2021-07-12T19:29:47Z
dc.date.available2021-07-12T19:29:47Z
dc.date.issued2020-06
dc.description.abstractEl nuevo coronavirus es el causante de la actual pandemia que se caracteriza por el cuadro de un síndrome respiratorio agudo. Históricamente ya existieron epidemias dadas por virus pertenecientes a la misma familia de coronavirus, como lo son el SARS-CoV y MERS-CoV causantes del síndrome respiratorio agudo severo y el síndrome respiratorio del medio oriente respectivamente. La estandarización de los datos epidemiológicos en la actualidad es un proceso de difícil unificación ya que las cifras de infectados y muertos varía cada día, esto por el curso actual de la pandemia. Las manifestaciones clínicas de los individuos infectados por SARS-CoV2 pueden ir desde muy leves hasta presentar cuadros graves que incluso pueden llegar a acabar con la vida de estos, sin embargo existe un porcentaje de pacientes que cursan con la enfermedad de manera asintomática. La manera más adecuada de establecer un diagnóstico acertado se basa en la detección del agente patógeno apoyado en los criterios de Koch. Actualmente hay una gran variedad de posibles terapias, de las cuales aún no existen los suficientes datos para avalar alguna de ellas, sin embargo nos encontramos en un periodo de prueba, se siguen realizando diversos estudios dirigidos hacia aquellos fármacos y regímenes de tratamiento más prometedores, hasta ahora con resultados poco alentadores, y a la espera de una vacuna muy necesaria en estos casos, para el control de la pandemia a medio y largo plazo.spa
dc.description.abstractThe new coronavirus is the cause of the current pandemic that is characterized by the picture of an acute respiratory syndrome. Historically, there have already been epidemics due to viruses belonging to the same coronavirus family, such as SARS-CoV and MERS-CoV, which cause severe acute respiratory syndrome and Middle Eastern respiratory syndrome, respectively. The standardization of epidemiological data at present is a difficult process to unify since the numbers of infected and dead vary every day, this due to the current course of the pandemic. The clinical manifestations of individuals infected with SARS-CoV2 can range from very mild to presenting severe symptoms that can even end their lives, however there is a percentage of patients who present with the disease asymptomatically. The most appropriate way to establish a correct diagnosis is based on the detection of the pathogen supported by Koch's criteria. Currently there are a wide variety of possible therapies, of which there are not yet enough data to support any of them, however we are in a trial period, various studies are still being conducted aimed at those drugs and most promising treatment regimens, so far with little encouraging results, and waiting for a much-needed vaccine in these cases, to control the pandemic in the medium and long term.eng
dc.format.mimetypepdfspa
dc.identifier.urihttps://hdl.handle.net/20.500.12442/7978
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCoronavirusspa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectHidroxicloroquinaspa
dc.subjectRemdesivirspa
dc.subjectACE-2spa
dc.subjectCoronaviruseng
dc.subjectCOVID-19eng
dc.subjectSARS-CoV-2eng
dc.subjectHydroxychloroquineeng
dc.subjectRemdesivireng
dc.subjectACE-2eng
dc.titleCovid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19spa
dc.type.driverinfo:eu-repo/semantics/bachelorThesiseng
dc.type.spaTrabajo de grado - pregradospa
dcterms.referencesMalik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40(1):68‐76. DOI:10.1080/01652176.2020.1727993eng
dcterms.referencesHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395 (10223): 497-506. DOI:https://doi.org/10.1016/S0140-6736(20)30183-5eng
dcterms.referencesWang, H., Wang, Z., Dong, Y. y col. Estimación ajustada por fase del número de casos de Enfermedad por Coronavirus 2019 en Wuhan, China. Cell Discov 6, 10 (2020). DOI:https://doi.org/10.1038/s41421-020-0148-0.spa
dcterms.referencesKamel Boulos, M.N., Geraghty, E.M. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int J Health Geogr 19, 8 (2020). DOI:https://doi.org/10.1186/s12942-020-00202-8.eng
dcterms.referencesThe Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly, 2020, 2(8): 113-122.eng
dcterms.referencesTian S, Hu N, Lou J, Chen K, Kang X, Xiang Z et al. Characteristics of COVID-19 infection in Beijing JOURNAL OF INFECTION. 2020; 80 (4): 401-406. DOI:https://doi.org/10.1016/j.jinf.2020.02.018eng
dcterms.referencesSinghal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281‐286. DOI:10.1007/s12098-020-03263-6eng
dcterms.referencesChen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7eng
dcterms.referencesZhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062. DOI:https://doi.org/10.1016/S0140-6736(20)30566-3eng
dcterms.referencesGuan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.DOI: 10.1056/NEJMoa2002032eng
dcterms.referencesXia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults. Pediatric Pulmonology. 2020;55(5):1169-1174. DOI: 10.1002 / ppul.24718eng
dcterms.referencesGuo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. 2020;7(1). DOI: 10.1186 / s40779-020-00240-0eng
dcterms.referencesHamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology. 2004;203(2):631-637. DOI: 10.1002/path.1570eng
dcterms.referencesAburizaiza A, Mattes F, Azhar E, Hassan A, Memish Z, Muth D et al. Investigation of Anti-Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012. Journal of Infectious Diseases. 2013;209(2):243-246. DOI: 10.1093/infdis/jit589eng
dcterms.referencesYu F, Du L, Ojcius D, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes and Infection. 2020;22(2):74-79. DOI: 10.1016/j.micinf.2020.01.003eng
dcterms.referencesWang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. DOI:10.1038/s41422- 020-0282-0eng
dcterms.referencesSanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824–1836. DOI:10.1001/jama.2020.6019.eng
dcterms.referencesGautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. DOI:10.1016/j. ijantimicag.2020.105949eng
dcterms.referencesChen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). DOI:10.3785/j.issn.1008-9292.2020.03.03eng
dcterms.referencesKadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-214. DOI:10.1073/pnas.1617020114eng
dcterms.referencesKhamitov RA, Loginova SIa, Shchukina VN,Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian]. Vopr Virusol. 2008;53(4):9-13. PMID: 18756809eng
dcterms.referencesWang Z, Yang B, Li Q,Wen L, Zhang R. Clinical Features of 69 cases with coronavirus disease 2019 inWuhan, China. Clin Infect Dis. DOI:10.1093/cid/ciaa272eng
dcterms.referencesSheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. DOI:10.1038/s41467-019-13940-6eng
dcterms.referencesJacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388(10043):498-503. DOI:10.1016/S0140-6736(16)30386-5eng
dcterms.referencesFerner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. Published 2020 Apr 8. DOI:10.1136/bmj.m1432eng
dcterms.referencesSiegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60(5): 1648-1661. DOI:10.1021/acs.jmedchem.6b01594eng
dcterms.referencesAl-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615. DOI:10.1016/j.tmaid.2020.101615eng
dcterms.referencesWorld Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. Published October 2018. Accessed March 20, 2020. https://www.who.int/ebola/drc-2018/summaries-of-evidenceexperimental-therapeutics.pdfeng
dcterms.referencesHolshue ML, DeBolt C, Lindquist S, et al; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. DOI:10.1056/NEJMoa2001191eng
dcterms.referencesStockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. DOI:10.1371/journal.pmed.0030343eng
dcterms.referencesMorra ME, Van Thanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28 (3):e1977. DOI:10.1002/rmv.1977eng
dcterms.referencesTotura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397-412. DOI:10.1080/ 17460441.2019.1581171eng
dcterms.referencesde Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92(pt 11):2542-2548. DOI:10.1099/ vir.0.034983-0eng
dcterms.referencesLi G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150. DOI:10.1038/d41573- 020-00016-0eng
dcterms.referencesRossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227-230. DOI:10.1016/j.jiph.2016. 04.001eng
dcterms.referencesHoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. DOI:10.1016/j.cell.2020.02.052eng
dcterms.referencesAmerican Heart Association. Patients taking angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blocker (ARB) medications should continue therapy as prescribed [news release]. Accessed March 18, 2020. https://newsroom.heart.org/ news/patients-taking-ace-i-and-arbs-who-contract- covid-19-should-continue-treatment-unless- otherwise-advised-by-their-physicianeng
dcterms.referencesEuropean Society for Cardiology. Position statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Accessed March 18, 2020. https://www.escardio.org/Councils/Council- on-Hypertension-(CHT)/News/position- statement-of-the-esc-council-on-hypertension-on- ace-inhibitors-and-angeng
dcterms.referencesArabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709. DOI:10.1186/s40064-015-1490-9eng
dcterms.referencesHung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456. DOI:10.1093/cid/ciq106eng
dcterms.references6. Mehra M, Desai S, Ruschitzka F, Patel A. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020 ;DOI: https://doi.org/10.1016/S0140-6736(20)31180-6.eng
dcterms.referencesBrunton L, Hilal-Dandan R, Knollmann B. Goodman & Gilman's The pharmacological basis of therapeutics. 13th ed. Auckland;976.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersioneng
sb.programaMedicinaspa
sb.sedeSede Barranquillaspa

Archivos

Colecciones

Pregrado
Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca